Over 250 healthcare investors, pharma / biotech partners and groundbreaking startups joined Mount Sinai to share successes and strategies that enhance innovation ecosystems last month at the JP Morgan Healthcare Investment Conference in San Francisco.
Diversity is key
Diversity has become a key strategy for innovation, as it brings a depth and breadth of perspectives that inform development of products and services. “We aim to strengthen the role of women and underserved minorities in our discovery process,” said Gary Butts, MD, Chief Diversity and Inclusion Office at the Mount Sinai Health System. Leveraging this strategy is critical, given that Mount Sinai has a highly diverse research enterprise, clinical setting and patient population. …
Tacitus Therapeutics exclusively licenses technology for expansion, differentiation and engineering of hematopoietic stem cells for use in therapeutic applications
Tacitus Therapeutics, a clinical-stage company, has launched in collaboration with the Mount Sinai Health System to develop stem cell therapies initially targeting blood cancers and related clotting disorders. Their first therapy, HSC100, currently is being investigated in a Phase I clinical trial*.
Tacitus is building upon technology developed by and exclusively licensed from Mount Sinai. Based on research by scientific co-founders Ronald Hoffman, M.D., and Camelia Iancu-Rubin, Ph.D., the technology includes proprietary cell expansion, differentiation and engineering methods. …
Mount Sinai Innovation Partners (MSIP) participated in several conferences and events to wrap up 2019, gathering thought leaders and industry experts to discuss best practices on building a strong life science ecosystem for the purpose of helping patient populations. These events included discussions on the future of medicine and trends across the healthcare innovation space, offering an opportunity to share how the Mount Sinai Health System delivers in these areas through its technology commercialization efforts.
Erik Lium, PhD, President, MSIP, Executive Vice President and Chief Commercial Innovation Officer, Mount Sinai Health System, shared the Mount Sinai perspective with the audience and engaged in enlightening discussion with fellow panelists. …
Nines’ unique approach to teleradiology reimagines radiology together with engineering and data science prowess to bring a new level of patient care
Nines debuts as the first-of-its-kind teleradiology practice that combines top quality radiologists and world-class engineering to deliver high-quality diagnostics and priority-driven patient care decisions.
“We have a fundamental belief that radiology reimagined with modern data science can significantly improve the lives of patients and clinicians alike,” said co-founder and CEO David Stavens. “We’re pioneering new approaches and innovations from clinical care, engineering and data science. Radiologists at Nines are care providers, innovators, builders, and thought leaders. …
The Human Immune Monitoring Center (HIMC) at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo® (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology company Regeneron Pharmaceuticals, Inc and Sanofi.
While immunotherapy has revolutionized the field of oncology, there are still key questions that remain — such as learning more about how these drugs work in human cancer — and many patients still fail to respond to these therapies, leaving a need to better understand how FDA-approved immunotherapies work and how we can use emerging therapies to further improve response rates to treatment. In a phase I clinical trial led by Thomas Marron, MD, PhD, Assistant Director of Early Phase and Immunotherapy Trials at The Tisch Cancer Institute at Mount Sinai, the HIMC will assess the clinical efficacy and response of patients to cemiplimab therapy in early-stage non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and head and neck squamous cell carcinoma (HNSCC). The HIMC will utilize optimized techniques to deeply interrogate the changes induced by these novel therapies within the tumor. …
Clinic and research lab offers patients access to comprehensive health assessment, expands clinical understanding of disease prevention and provides wealth of health outcomes data
Onegevity Health, LLC, a New York City-based health technology company focused on biometric data, artificial intelligence and personalized wellness, has acquired the global licensing rights to Mount Sinai’s Lab100, a clinic and research lab that uses precision diagnostics to empower patients and help scientists advance our understanding of human health. …
The Mount Sinai Health System and SAP Foundry in Hudson Yards, New York partnered with other forward-thinking organizations to host the recent installment of The Open Innovation In Healthcare Pop-Up series on October 1. The Pop-Up is a convener for healthcare executives and innovators to gather and pioneer thoughtful conversations that most likely would not occur otherwise. The theme, women and underserved entrepreneurs, showcased stakeholders from across the health ecosystem working on not only the unmet needs in women’s health but also the ways to improve support for founders’ building solutions to those problems.
To an audience of over 120 people, Erik Lium, PhD, Executive Vice President, Mount Sinai Innovation Partners, kicked off the day with a warm welcome alongside Deepak Krishnamurthy, Chief of Strategy, SAP. …
The inaugural iLABS event took place on September 19, showcasing the latest technologies in ophthalmology from Mount Sinai Health System innovators. Hosted by the Mount Sinai Department of Ophthalmology, the New York Eye and Ear (NYEE) Infirmary Program for Innovation and Technology, and Mount Sinai Innovation Partners (MSIP), iLABS featured the cutting-edge science that is paving the way for new solutions in eye care.
Researchers presented discoveries and concepts on commercial success to a room full of fellow thought leaders, startup founders, investors, and potential partners, with the overarching goal of driving forward technology to help the patient population.
“This is a place where you can come and share ideas,” said Sean Ianchulev, MD, Director, Technology and Innovation, NYEE. “We have great talent here at Mount Sinai, and it’s great to see different perspectives: iLABS will bring together companies and catalysts who can offer information about resources at both Mount Sinai and the local area.” Speakers covered a wide range of topics in ophthalmology, including virtual reality, micro-robotic, artificial intelligence for retinal diagnosis, and more. …
Sinai BioDesign, an organization of the Icahn School of Medicine at Mount Sinai focused on the development of biomedical technologies, hosted U.S. Food and Drug Administration (FDA) representative Joshua Chetta on October 1 to discuss the regulations and requirements for device submission and review. Chetta offered an overview on Investigational Device Exemptions (IDEs) and Q-Submissions, two of the many forms of reviewal regulated by the FDA for research discoveries.
As a member of the Policy and Operations Team in the Office of Clinical Evidence and Analysis, Chetta shared the main goal of the FDA’s processes: to make sure patients have access to high quality, safe medical devices. …
Organizational culture is defined as the underlying beliefs, values, and ways of interacting that contribute to the unique social and psychological environment of an organization. There are various types of organizational culture, but especially in the face of open innovation in health care, an organization will undoubtedly be tested. Teams must be prepared to effectively communicate, engage and pay attention to behaviors more closely than ever before.
The Mount Sinai Health System combines the Icahn School of Medicine at Mount Sinai and eight hospital campuses to provide the highest quality healthcare throughout the New York metropolitan area. Through an open innovation model, we provide care that optimizes health to eradicate disease and improve outcomes on a global basis. …
About
